Bolt Biotherapeutics Total Liabilities
Bolt Biotherapeutics total liabilities. Based on the latest financial reports, Bolt Biotherapeutics (BOLT) has total liabilities worth $30.24 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Bolt Biotherapeutics (BOLT) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Bolt Biotherapeutics (2018–2025)
Total liabilities of Bolt Biotherapeutics from 2018 to 2025. This chart illustrates how Bolt Biotherapeutics's total liabilities have evolved over time, based on quarterly financial data. Explore Bolt Biotherapeutics long-term investment allocation to see how much of total assets are deployed in long-term investments.
Bolt Biotherapeutics Competitors by Total Liabilities
The table below lists competitors of Bolt Biotherapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Target Healthcare REIT Ltd
LSE:THRL
|
UK | GBX236.22 Million |
|
Godolphin Resources Ltd
AU:GRL
|
Australia | AU$207.01K |
|
Trivarx Ltd
AU:TRI
|
Australia | AU$565.64K |
|
Avon Protection PLC
LSE:AVON
|
UK | GBX134.19 Million |
|
Kesla Oyj A
HE:KELAS
|
Finland | €19.34 Million |
|
Asmallworld AG
SW:ASWN
|
Switzerland | CHF7.49 Million |
|
Locate Technologies Ltd
AU:LOC
|
Australia | AU$5.58 Million |
|
Morgan Advanced Materials plc
LSE:MGAM
|
UK | GBX697.60 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Bolt Biotherapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BOLT total assets.
Liquidity & Leverage Metrics
Bolt Biotherapeutics Total Liabilities Ratios Explained
Bolt Biotherapeutics total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bolt Biotherapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bolt Biotherapeutics (2018–2025)
The table below shows the annual total liabilities of Bolt Biotherapeutics from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $30.24 Million | -28.73% |
| 2024-12-31 | $42.43 Million | -9.80% |
| 2023-12-31 | $47.04 Million | -16.44% |
| 2022-12-31 | $56.30 Million | -2.25% |
| 2021-12-31 | $57.60 Million | -61.98% |
| 2020-12-31 | $151.49 Million | +60.66% |
| 2019-12-31 | $94.29 Million | +195.42% |
| 2018-12-31 | $31.92 Million | -- |
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agon… Read more